Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for ...

Glenmark Therapeutics Inc., USA announced today the launch of its Polyethylene Glycol 3350, Powder for Solution, an ...

Glenmark Pharmaceuticals has announced the launch of 'Polyethylene Glycol 3350 Powder for Solution' as on OTC product in the US market.

According to Nielsen syndicated data for the latest 52 weeks' period ending 22 February 2025, the MiraLAX Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 ...

Contribute to aakesh123242/market0 development by creating an account on GitHub.

Glenmark Pharmaceuticals launches polyethylene glycol 3350, a constipation treatment medicine in the US. The OTC product aims ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously ...

USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX®2 Powder for Solution ...

Paid Advertisement Methylene blue has gained widespread attention for its potential effects on focus, mood, and energy.

Glenmark Therapeutics launches polyethylene glycol 3350, powder for solution, 17 grams/capful in US: Our Bureau, Mumbai Monday, March 10, 2025, 14:15 Hrs [IST] Glenmark Therapeuti ...

Real-world data support clinical trial results showing less gastrointestinal toxicity with use of a rectal spacer during prostate cancer radiation therapy.